Crescent Biopharma (CBIO) Amortization of Deferred Charges (2021 - 2026)
Crescent Biopharma (CBIO) posted quarterly Amortization of Deferred Charges of $101000.0 for Q2 2026, up 339.13% year-over-year from $23000.0 in Q2 2025, and up 4.12% quarter-over-quarter from $97000.0 in Q1 2026.
Crescent Biopharma (CBIO) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Amortization of Deferred Charges for 6 consecutive years, with $101000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortization of Deferred Charges rose 339.13% year-over-year to $101000.0; the TTM figure through Jun 2026 stood at $387000.0 (up 1582.61% YoY), while the FY2025 annual figure was $212000.0, down 47.35% from the prior year.
- Amortization of Deferred Charges rose to $101000.0 in Q2 2026 per CBIO's latest filing, from $97000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $227190.0 in Q3 2023 and bottomed at $23000.0 in Q2 2025.
- Historically, Amortization of Deferred Charges has averaged $162324.5 across 5 years, with a median of $187482.0 in 2023.
- Annual changes were most pronounced in 2025 — Amortization of Deferred Charges tumbled 86.79% — and 2026, when it soared 339.13%.
- Crescent Biopharma's Amortization of Deferred Charges stood at $213848.0 in 2022, then retreated by 12.33% to $187482.0 in 2023, then decreased by 7.17% to $174048.0 in 2024, then tumbled by 45.42% to $95000.0 in 2025, then advanced by 6.32% to $101000.0 in 2026.
- Business Quant data shows CBIO's Amortization of Deferred Charges at $101000.0 in Q2 2026, $97000.0 in Q1 2026, and $95000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101,000.00 |
| Jun 30, 2026 | 101,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2024 | 174,048.00 |
| Jun 30, 2024 | 174,048.00 |
| Mar 31, 2024 | 169,571.00 |
| Mar 31, 2024 | 169,571.00 |
| Dec 31, 2023 | 187,482.00 |
| Dec 31, 2023 | 187,482.00 |
| Sep 30, 2023 | 227,190.00 |
| Sep 30, 2023 | 227,190.00 |
| Jun 30, 2023 | 222,447.00 |
| Jun 30, 2023 | 222,447.00 |